Patents by Inventor Federico Maisano
Federico Maisano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11905323Abstract: The invention discloses a recombinant protein (P-selectin glycoprotein ligand-1 and Neural Retina-specific Leucine Zipper) PSGL-1-NRL chimeric protein comprising a Selectin Binding domain and a non-covalent dimerization domain, which is a leucine zipper and is more preferably the leucine zipper domain of the human or mouse Neural Retina-specific Leucine Zipper. The chimeric protein further comprises a covalent dimerization domain with at least one cysteine suitable to form a disulfide bridge with another chimeric protein to form a homodimer. In the chimeric protein, the PSGL-1 domain corresponds to the extracellular region of Human PSGL-1 and is more preferably the selectin binding region of the mature protein. The chimeric protein is correctly post-translationally modified and is efficiently expressed in a mammalian system. It is sulfated, O-linked glycosylated and sialylated and binds P, E and L selectin, allowing in vivo and in vitro targeting for diagnostic or therapeutic purposes.Type: GrantFiled: May 18, 2022Date of Patent: February 20, 2024Assignee: Bracco SuisseInventors: Federico Maisano, Federico Crivellin, Thierry Bettinger, Philippe Bussat, Samir Cherkaoui, Christian Koller, Adrian Lobito
-
Publication number: 20220389080Abstract: The invention discloses a recombinant protein (P-selectin glycoprotein ligand-1 and Neural Retina-specific Leucine Zipper) PSGL-1-NRL chimeric protein comprising a Selectin Binding domain and a non-covalent dimerization domain, which is a leucine zipper and is more preferably the leucine zipper domain of the human or mouse Neural Retina-specific Leucine Zipper. The chimeric protein further comprises a covalent dimerization domain with at least one cysteine suitable to form a disulfide bridge with another chimeric protein to form a homodimer. In the chimeric protein, the PSGL-1 domain corresponds to the extracellular region of Human PSGL-1 and is more preferably the selectin binding region of the mature protein. The chimeric protein is correctly post-translationally modified and is efficiently expressed in a mammalian system. It is sulfated, O-linked glycosylated and sialylated and binds P, E and L selectin, allowing in vivo and in vitro targeting for diagnostic or therapeutic purposes.Type: ApplicationFiled: May 18, 2022Publication date: December 8, 2022Applicant: Bracco Suisse SAInventors: Federico MAISANO, Federico CRIVELLIN, Thierry BETTINGER, Philippe BUSSAT, Samir CHERKAOUI, Christian KOLLER, Adrian LOBITO
-
Patent number: 11370826Abstract: The invention discloses a recombinant protein (P-selectin glycoprotein ligand-1 and Neural Retina-specific Leucine Zipper) PSGL-1-NRL chimeric protein comprising a Selectin Binding domain and a non-covalent dimerization domain, which is a leucine zipper and is more preferably the leucine zipper domain of the human or mouse Neural Retina-specific Leucine Zipper. The chimeric protein further comprises a covalent dimerization domain with at least one cysteine suitable to form a disulfide bridge with another chimeric protein to form a homodimer. In the chimeric protein, the PSGL-1 domain corresponds to the extracellular region of Human PSGL-1 and is more preferably the selectin binding region of the mature protein. The chimeric protein is correctly post-translationally modified and is efficiently expressed in a mammalian system. It is sulfated, O-linked glycosylated and sialylated and binds P, E and L selectin, allowing in vivo and in vitro targeting for diagnostic or therapeutic purposes.Type: GrantFiled: February 9, 2017Date of Patent: June 28, 2022Assignee: Bracco Suisse SAInventors: Federico Maisano, Federico Crivellin, Thierry Bettinger, Philippe Bussat, Samir Cherkaoui, Christian Koller, Adrian Lobito
-
Patent number: 10870649Abstract: The application relates to a process for the synthesis of a Near Infra-Red (NIR) fluorescent probe which is a cRGD-Cy5.5 conjugate of formula (I) known as DA364 comprising an aza-bicycloalkane based cyclic peptide labelled with a Cy5.5 dye moiety and used in the guided surgery of tumors and pathologic regions.Type: GrantFiled: April 10, 2018Date of Patent: December 22, 2020Assignee: BRACCO IMAGING SPAInventors: Luciano Lattuada, Federica Buonsanti, Federico Crivellin, Fulvio Ferretti, Federico Maisano, Laura Orio, Lorena Pizzuto
-
Publication number: 20200055855Abstract: The application relates to a process for the synthesis of a Near Infra-Red (NIR) fluorescent probe which is a cRGD-Cy5.5 conjugate of formula (I) known as DA364 comprising an aza-bicycloalkane based cyclic peptide labelled with a Cy5.5 dye moiety and used in the guided surgery of tumors and pathologic regions.Type: ApplicationFiled: April 10, 2018Publication date: February 20, 2020Applicant: BRACCO IMAGING SPAInventors: Luciano LATTUADA, Federica BUONSANTI, Federico CRIVELLIN, Fulvio FERRETTI, Federico MAISANO, Laura ORIO, Lorena PIZZUTO
-
Patent number: 10457635Abstract: The present invention relates to a process for the preparation of the mono sodium salt of the derivative 3,5-diiodo-O-[3-iodo-4-(sulphooxy)phenyl]-L-tyrosine (T3S) by starting from the corresponding phenolic compound, in the presence of chlorosulfonic acid and dimethylacetamide as a solvent. The so obtained T3S compound may conveniently be isolated in a pure form as a solid in good yields. The present invention further relates to the process for T3S preparation, wherein the starting reagent is T2 and further comprising the formulation of such compound in tablets. Furthermore, the invention discloses non-radioactive immunoassays based on T3S derivatives.Type: GrantFiled: December 22, 2017Date of Patent: October 29, 2019Assignee: BRACCO IMAGING S.p.A.Inventors: Pier Lucio Anelli, Maria Argese, Valeria Boi, Livio Cavalieri, Laura Galimberti, Sonia Gazzetto, Luciano Lattuada, Federico Maisano, Giovanni Rivolta, Fulvia Vella
-
Publication number: 20190048062Abstract: The invention discloses a recombinant protein (P-selectin glycoprotein ligand-1 and Neural Retina-specific Leucine Zipper) PSGL-1-NRL chimeric protein comprising a Selectin Binding domain and a non-covalent dimerization domain, which is a leucine zipper and is more preferably the leucine zipper domain of the human or mouse Neural Retina-specific Leucine Zipper. The chimeric protein further comprises a covalent dimerization domain with at least one cysteine suitable to form a disulfide bridge with another chimeric protein to form a homodimer. In the chimeric protein, the PSGL-1 domain corresponds to the extracellular region of Human PSGL-1 and is more preferably the selectin binding region of the mature protein. The chimeric protein is correctly post-translationally modified and is efficiently expressed in a mammalian system. It is sulfated, O-linked glycosylated and sialylated and binds P, E and L selectin, allowing in vivo and in vitro targeting for diagnostic or therapeutic purposes.Type: ApplicationFiled: February 9, 2017Publication date: February 14, 2019Applicant: Bracco Suisse SAInventors: Federico MAISANO, Federico CRIVELLIN, Thierry BETTINGER, Philippe BUSSAT, Samir CHERKAOUI, Christian KOLLER, Adrian LOBITO
-
Publication number: 20180118669Abstract: The present invention relates to a process for the preparation of the mono sodium salt of the derivative 3,5-diiodo-O-[3-iodo-4-(sulphooxy)phenyl]-L-tyrosine (T3S) by starting from the corresponding phenolic compound, in the presence of chlorosulfonic acid and dimethylacetamide as a solvent. The so obtained T3S compound may conveniently be isolated in a pure form as a solid in good yields. The present invention further relates to the process for T3S preparation, wherein the starting reagent is T2 and further comprising the formulation of such compound in tablets. Furthermore, the invention discloses non-radioactive immunoassays based on T3S derivatives.Type: ApplicationFiled: December 22, 2017Publication date: May 3, 2018Applicant: BRACCO IMAGING S.p.A.Inventors: Pier Lucio ANELLI, Maria ARGESE, Valeria BOI, Livio CAVALIERI, Laura GALIMBERTI, Sonia GAZZETTO, Luciano LATTUADA, Federico MAISANO, Giovanni RIVOLTA, Fulvia VELLA
-
Patent number: 9567350Abstract: The present invention generally relies on a process for the preparation of chelated compounds, comprising the selective interaction between a solid matrix and a chelating agent. In more details, the present invention enables the preparation of chelated compounds useful as diagnostic agents, in high yields and in a reliable way.Type: GrantFiled: February 16, 2015Date of Patent: February 14, 2017Assignee: BRACCO IMAGING S.P.A.Inventors: Federico Maisano, Federico Crivellin
-
Patent number: 9468619Abstract: The invention regards the use of triiodothyronine sulfate, commonly named T3S, as a medicament having thyromimetic activity for the treatment of pathologies due to organic deficiency of triiodothyronine (T3), as such or in association with thyroxine (T4), and pharmaceutical formulations for oral administration thereof.Type: GrantFiled: June 13, 2013Date of Patent: October 18, 2016Assignee: Bracco S.P.A.Inventors: Aldo Pinchera, Livio Cavalieri, Federico Maisano, Giovanni Rivolta, Ferruccio Santini, Fulvia Vella
-
Patent number: 9439883Abstract: The invention regards the use of triiodothyronine sulfate, commonly named T3S, as a medicament having thyromimetic activity for the treatment of pathologies due to organic deficiency of triiodothyronine (T3), as such or in association with thyroxine (T4), and pharmaceutical formulations for oral administration thereof.Type: GrantFiled: June 13, 2013Date of Patent: September 13, 2016Assignee: Bracco S.P.A.Inventors: Aldo Pinchera, Livio Cavalieri, Federico Maisano, Giovanni Rivolta, Ferruccio Santini, Fulvia Vella
-
Publication number: 20150158887Abstract: The present invention generally relies on a process for the preparation of chelated compounds, comprising the selective interaction between a solid matrix and a chelating agent. In more details, the present invention enables the preparation of chelated compounds useful as diagnostic agents, in high yields and in a reliable way.Type: ApplicationFiled: February 16, 2015Publication date: June 11, 2015Applicant: BRACCO IMAGING S.P.A.Inventors: Federico MAISANO, Federico CRIVELLIN
-
Patent number: 9044441Abstract: The invention regards the use of triiodothyronine sulfate, commonly named T3S, as a medicament having thyromimetic activity for the treatment of pathologies due to organic deficiency of triiodothyronine (T3), as such or in association with thyroxine (T4), and pharmaceutical formulations for oral administration thereof.Type: GrantFiled: January 31, 2013Date of Patent: June 2, 2015Assignee: Bracco S.P.A.Inventor: Federico Maisano
-
Patent number: 8987508Abstract: The present invention generally relies on a process for the preparation of chelated compounds, comprising the selective interaction between a solid matrix and a chelating agent. In more details, the present invention enables the preparation of chelated compounds useful as diagnostic agents, in high yields and in a reliable way.Type: GrantFiled: December 15, 2010Date of Patent: March 24, 2015Assignee: Bracco Imaging S.p.A.Inventors: Federico Maisano, Federico Crivellin
-
Publication number: 20140024717Abstract: The present invention relates to a process for the preparation of the mono sodium salt of the derivative 3,5-diiodo-O-[3-iodo-4-(sulphooxy)phenyl]-L-tyrosine (T3S) by starting from the corresponding phenolic compound, in the presence of chloro-sulfonic acid and dimethylacetamide as a solvent. The so obtained T3S compound may conveniently be isolated in a pure form as a solid in good yields. The present invention further relates to the process for T3S preparation, wherein the starting reagent is T2 and further comprising the formulation of such compound in tablets. Furthermore, the invention discloses non-radioactive immunoassays based on T3S derivatives.Type: ApplicationFiled: April 5, 2012Publication date: January 23, 2014Applicant: BRACCO IMAGING S.p.A.Inventors: Pier Lucio Anelli, Maria Argese, Luciano Lattuada, Federico Maisano, Sonia Gazzetto, Laura Galimberti, Valeria Boi, Giovanni Rivolta, Livio Cavalieri, Fulvia Vella
-
Publication number: 20130281536Abstract: The invention regards the use of triiodothyronine sulfate, commonly named T3S, as a medicament having thyromimetic activity for the treatment of pathologies due to organic deficiency of triiodothyronine (T3), as such or in association with thyroxine (T4), and pharmaceutical formulations for oral administration thereof.Type: ApplicationFiled: June 13, 2013Publication date: October 24, 2013Inventors: Aldo PINCHERA, Livio CAVALIERI, Federico MAISANO, Giovanni RIVOLTA, Ferruccio SANTINI, Fulvia VELLA
-
Publication number: 20120245333Abstract: The present invention generally relies on a process for the preparation of chelated compounds, comprising the selective interaction between a solid matrix and a chelating agent. In more details, the present invention enables the preparation of chelated compounds useful as diagnostic agents, in high yields and in a reliable way.Type: ApplicationFiled: December 15, 2010Publication date: September 27, 2012Applicant: BRACCO IMAGING S.P.A.Inventors: Federico Maisano, Federico Crivellin
-
Publication number: 20120165211Abstract: The present invention refers to human antibodies derived from human antibody libraries prepared from atherosclerotic plaques. It further refers to human antibodies able to immunologically recognize both human transgelin or fragments thereof and a protein with at least 50% similarity to OmpK36 (Outer membrane protein, Klebsiella, K36; GI: 295881594) or fragments thereof. Human transgelin is preferably transgelin 1 (Accession N° Q01995, GI:48255907). The antibodies further recognize an antigen in the atherosclerotic plaque and are useful for the preparation of immunodiagnostic reagents or assays to detect atherogenic diseases. The invention also relates to the use of anti-TAGLN monoclonal antibodies, showing cross-reactivity with a bacterial antigen having at least 50% similarity with OmpK36, for detecting antigens in the atherosclerotic plaque or as atherosclerotic related reagents in an immuno-competition assay.Type: ApplicationFiled: January 13, 2012Publication date: June 28, 2012Applicant: BRACCO IMAGING S.P.A.Inventors: Roberto BURIONI, Filippo CANDUCCI, Massimo CLEMENTI, Federico MAISANO
-
Publication number: 20110245342Abstract: The invention regards the use of triiodothyronine sulfate, commonly named T3S, as a medicament having thyromimetic activity for the treatment of pathologies due to organic deficiency of triiodothyronine (T3), as such or in association with thyroxine (T4), and pharmaceutical formulations for oral administration thereof.Type: ApplicationFiled: April 8, 2011Publication date: October 6, 2011Applicant: Bracco S.p.A.Inventors: Aldo PINCHERA, Ferruccio Santini, Giovanni Rivolta, Livio Cavalieri, Fulvia Vella, Federico Maisano
-
Publication number: 20060120959Abstract: The invention provides chemical conjugates between an immunoglobulin Fab fragment and molecular entities imparting diagnostic or therapeutic utility, whereby the only sites of conjugation on the Fab fragment are one or both of the sulfhydryl groups deriving from the selective and quantitative reduction of the inter-chain disulfide bond of said Fab fragment and whereby said molecular entities imparting diagnostic or therapeutic utility have at least one free sulfhydryl-reactive group, characterized in that the conjugation stoichiometric molar ratio molecular entity to Fab fragment is in the range from 0.95 to 1.05 or in the range from 1.95 to 2.05. The invention also provides a process for preparing said conjugates and pharmaceutical compositions thereof.Type: ApplicationFiled: November 10, 2003Publication date: June 8, 2006Applicant: Bracco Imaging S.P.A.Inventors: Christoph De Haen, Federico Maisano